Ahead of CapMan's Q1 2026 results on 6 May, we cut our EBIT estimates, mainly to reflect a lower lev...
No new information regarding the possible divestment of the ESL Shipping segment has been released.
We update our forecasts and Base Case following Lime’s Q1 2026 results, which came in slightly ahead...
Redeye comments on Vertiseit’s Q1 2026 report. While EBITDA-CAPEX was 32% below our expectations, dr...
H1 will be clearly slower than H2/26, as project execution will accelerate during the latter half of...
* Sales SEK 44m (-5% vs. ABGSCe), EBIT -5.5m (vs. -3.
Redeye gives a short comment on the announced rights issue.
The Top Picks Investment Committee remains active in a market that has finally started to move after...
Redeye comments on Neola Medical’s update regarding the analysis of the Swedish clinical study.
* Q1 sales of SEK 44m (-11% y-o-y), -5% vs. ABGSCe * EBIT SEK -5.
Redeye comments on Lime’s Q1 2026 report, which showed an acceleration in ARR growth alongside a sol...
Aspo reports Q1 results on Apr 27. We believe FY’26 EBITA will improve by at least some amount thank...
Redeye updates its estimates and fair value range following Waystream’s Q1 report, which came in sof...
Ahead of Taaleri's Q1 results on 29 April, we make several estimate changes.
As expected, Careium has been selected as part of the new Digital Security Services framework for or...
Mr. Cavander will start in his new role on 8 May 2026.
EUZ Q1 26 results are due on May 12. We expect sales of € 72.
* Positive PW: Adj. EBITA +36% vs ABG (mid-point) * Temporary boost from memory crisis and positive ...
We expect modest revenue growth in Q1, supported by project completions, but with some near-term mar...
Vi ser att kvartal-för-kvartal-fallet i värderingar för mjukvaru- och marknadsplatsjämförelsebolag s...
We see the q/q drop in valuation for software and marketplace peers creating a soft backdrop for VNV...